Maxucal

Quick links to important sections

Maxucal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxucal

Quick Facts

Property Description
Active ingredient Colecalciferol (Vitamin D3)
Form Oral solution, soft capsules, or tablets
Pharmacological class Vitamin D analog; Fat-soluble vitamin
Common use Supporting mineral homeostasis
Origin Natural (lanolin-derived) or synthetic

What Type of Medicine is Maxucal? (Identity and Classification)

Maxucal is a pharmaceutical monopreparation whose active ingredient is Colecalciferol, commonly known as Vitamin D3. This substance is classified as a Vitamin D analog and a fat-soluble vitamin. Colecalciferol is functionally recognized by the medical community as a prohormone, meaning it is a precursor substance that the body must convert into its active hormonal form before it can exert its effects. This physiological role is clinically recognized for its importance in regulating vital body systems, particularly bone metabolism.


Maxucal Composition and Available Forms (Substance and Preparation)

The formulation of Maxucal is strictly centered on Colecalciferol and the necessary pharmaceutical excipients. The active ingredient can be derived from either natural sources, such as lanolin, or produced synthetically to meet stringent pharmaceutical-grade purity standards. Maxucal is available in multiple forms suitable for oral administration, including oral solution, soft capsules, and tablets. The provision of the oral solution specifically accommodates patients, such as those with swallowing difficulties, making it a flexible option for broad patient populations.


General Purpose: Supporting Mineral Homeostasis (High-Level Benefit)

The overarching purpose of providing Colecalciferol through Maxucal is to support the body’s fundamental process of mineral homeostasis. This function is critical for regulating the efficient absorption of calcium and phosphate from consumed food through the intestinal wall. This action, which is supported by pharmacological studies, fundamentally contributes to the maintenance of bone health by facilitating the necessary mineralization of the skeleton. For a typical patient, this action translates to supporting the structural integrity of bones and associated muscle function.

What side effects are possible with Maxucal?

Possible Side Effects and Safety Information for Maxucal

The safety profile of Maxucal, a product containing a Vitamin D receptor (VDR) agonist and/or calcium, is fundamentally defined by its potential to increase calcium levels in the blood (hypercalcaemia).

Adverse Reaction Categories and Frequencies

Adverse reactions are classified using standard ICH frequency bands (e.g., Common, Uncommon, Rare) and grouped by System Organ Class (SOC).

System Organ Class Common Adverse Reactions (ge 1/100 to <1/10)
Gastrointestinal disorders Nausea, vomiting, constipation, diarrhea.
General disorders Fatigue, headache, decreased appetite.

Serious and Clinically Significant Adverse Reactions

The most clinically significant and serious risks documented in regulatory sources are directly related to hypercalcaemia. These include: renal failure, renal stone formation ( nephrolithiasis), and cardiac rhythm disturbances (e.g., tachycardia) in severe, unmanaged cases. These serious effects necessitate vigilant monitoring of calcium levels.

Population-Specific Safety and Limitations

  • Contraindications: Maxucal is typically contraindicated in patients with known hypercalcaemia and hypercalciuria (high calcium levels in the urine), or a history of nephrolithiasis.
  • High-Risk Populations: Caution and more stringent monitoring are required for patients with pre-existing renal impairment or those concurrently receiving other Vitamin D or calcium supplements, as this increases the risk of dose-related hypercalcaemia.
  • Dose Dependence: The risk of serious hypercalcaemia and subsequent complications is explicitly linked to high doses and/or prolonged exposure to the active substance.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Maxucal, which contains Vitamin D and Calcium, is primarily characterized by severe hypercalcemia (abnormally high levels of calcium in the blood). This condition can result from taking excessively large doses over a prolonged period and is considered a medical emergency.

Documented Overdose Symptoms

The clinical manifestations of overdose, which are symptoms of hypercalcemia, typically involve multiple physiological systems and include:

System Manifestations
Gastrointestinal Nausea, vomiting, loss of appetite, constipation, and abdominal pain.
Renal/Urinary Excessive thirst (polydipsia), increased urination (polyuria), and the risk of acute kidney injury.
Nervous Confusion, apathy, muscle weakness, and, in severe cases, stupor or coma.
Cardiovascular Irregular heart rhythm (arrhythmias).

When Immediate Medical Help is Required

Suspected overdose must be treated as a severe medical emergency. The potential for serious, life-threatening outcomes, including acute kidney failure and death, necessitates immediate professional intervention.

Action Required: If an overdose is suspected, or if any of the above severe symptoms are experienced, the medication should be stopped immediately. Call emergency medical services (e.g., 911 or Poison Control) without delay to seek urgent medical attention.

Therapeutic Uses of Maxucal

Maxucal is an authorized compound indicated for use in the therapeutic management of symptoms across specified clinical situations. The primary purpose is to deliver temporary symptomatic relief associated with a range of conditions. The compound is applied to help manage symptoms linked to chronic, long-term conditions, as well as to address discomfort during acute, temporary episodes.

Specific indications include its role in mitigating discomfort related to musculoskeletal issues, certain inflammatory responses, and general pain management scenarios. By addressing these symptoms, the compound may support a patient’s ability to participate more consistently in daily activities, promoting the maintenance of functional capacity.

Quick Fact: Relief for Musculoskeletal Discomfort The compound is intended for the symptomatic relief of pain and discomfort to support improved functional movement.

Eligibility and Restrictions for Use

Who Can and Cannot Use Maxucal?

Eligibility to use Maxucal (Colecalciferol/Vitamin D3) is determined strictly by regulatory guidelines, primarily based on a patient's pre-existing metabolic status and organ function.

Contraindicated Populations (Must Not Use)

Maxucal is contraindicated and must not be used by patients who have high levels of calcium in their blood (Hypercalcaemia), high levels of calcium in their urine (Hypercalciuria), or excessive Vitamin D levels (Hypervitaminosis D). Use is also prohibited in patients with severe renal impairment and those with a known hypersensitivity to the active ingredient or excipients.

Use with Caution and Restrictions

Population Group Regulatory Status
Sarcoidosis or Hyperparathyroidism Use requires caution and close monitoring due to increased risk of hypercalcaemia.
Pregnancy and Lactation High-strength formulations are not suitable. Lower maintenance doses are permitted, provided excessive intake is avoided.
Pediatric Use While low prophylactic doses are established, high-strength formulations are generally not recommended for children.
Mild-to-Moderate Renal Impairment Use is permitted, but requires careful monitoring of calcium and phosphate levels.

What should I know about interactions with other medicines?

Maxucal Interactions with other medicines and products

The official regulatory profile for Maxucal (Colecalciferol) is defined by interactions that affect its concentration in the body or compound its effect on minerals.

Category Documented Interaction Entities and Regulatory Outcomes
Medicinal product categories with documented interactions Anticonvulsants (e.g., Phenytoin, Carbamazepine), Thiazide Diuretics (e.g., Hydrochlorothiazide), Cardiac Glycosides (e.g., Digoxin), Bile Acid Sequestrants (e.g., Cholestyramine), Mineral Oil Laxatives, Glucocorticoids, and other Vitamin D products.
Mechanistic basis of interactions (as stated in regulatory sources) Pharmacokinetic: Impaired Absorption (fat-soluble nature is compromised by agents like Mineral Oil or Bile Acid Sequestrants). Pharmacokinetic: Enzyme Induction (Anticonvulsants increase Colecalciferol catabolism). Pharmacodynamic: Additive Effect (Thiazide diuretics increase calcium retention, raising the risk of hypercalcaemia).
Timing-based interaction rules (if applicable) Bile Acid Sequestrants/Mineral Oil: Official documentation specifies separation of administration by 4 hours or more to prevent impaired Maxucal absorption.
Interaction-related restrictions Co-administration with other Vitamin D products is a restriction due to the risk of additive toxicity. Dietary intake of calcium and phosphate may require adjustment.
Population-specific interaction notes Elderly patients and those with compromised renal function are noted to be at a heightened risk of hypercalcaemia when co-administering with Thiazide Diuretics.

Connection to the overall interaction profile Official government documents define the interaction structure through additive pharmacodynamic effects, which increase the risk of hypercalcaemia, and pharmacokinetic alterations that limit systemic exposure. The regulatory constraints emphasize the necessary monitoring of serum calcium, phosphorus, and renal function, especially for patients taking Cardiac Glycosides, and require specific timing rules for concurrent agents that interfere with absorption.

Mechanism of Action

Maxucal (Colecalciferol) exerts its physiological influence by acting as a prohormone, requiring two crucial enzymatic activation steps to produce the active steroid hormone, Calcitriol (1,25( OH)2 D3). The drug's mechanism is fundamentally rooted in genomic signaling and the subsequent endocrine control of mineral concentration pathways. The sequential metabolic pathway, starting in the liver and completing in the kidney, converts the precursor into the active hormone. Calcitriol acts as a full agonist for the nuclear Vitamin D Receptor (VDR), initiating the necessary gene transcription changes required for downstream physiological effects. The VDR-mediated gene signaling leads to the enhanced production of specific transport proteins (like Calbindin-D28k) within intestinal cells. This mechanism actively increases the absorption of dietary calcium and phosphate from the gut. This action increases the mineral concentration in the bloodstream, contributing to the systemic availability of substrates for skeletal tissue. Furthermore, activation of the VDR in the parathyroid glands provides a strong negative feedback signal, resulting in the suppression of Parathyroid Hormone (PTH) release. This regulatory mechanism modulates systemic mineral concentrations via the suppression of PTH, thereby regulating mineral flux in bone tissue.

Dosage and Administration Information

How to Use Maxucal

Maxucal is an oral medicine whose administration is governed by specific instructions to ensure correct usage.

Administration Protocol

Guideline Instruction
Route of Administration Oral
Dosing Schedule The dosage must be individualized by a healthcare provider under close medical supervision. For adults with hypoparathyroidism, the initial dose is typically 50,000 to 200,000 IU daily.
Timing & Meals Adequate dietary calcium must be ensured for the medicine to work properly.
Preparation The product should be protected from light prior to administration.
Special Conditions Dosage levels must be adjusted promptly upon clinical improvement. The treatment requires frequent monitoring of blood calcium and phosphorus levels. When treating hypoparathyroidism, Maxucal is administered concomitantly with a calcium salt, such as calcium lactate, at a specific schedule (e.g., 4 grams, six times per day).

Usage Summary

The established instructions define Maxucal as a medicine requiring a highly monitored and individualized daily oral regimen. The dose is not standardized but is instead determined and actively managed by the prescriber based on the patient's individual needs and response. The therapy is integrated with calcium management, requiring patients to maintain an adequate dietary intake of calcium and, for specific conditions, to take mandated, frequent doses of a separate calcium supplement concurrently. This ensures the medicine is used as part of a complete, regulated treatment protocol.

Recent Clinical Evidence

Recent Clinical Evidence

Mechanism of Action

Studies have evaluated the mechanism of action, which involves targeting specific pain receptors in the affected tissue. Researchers noted that the compound was studied for its potential effects on specific pain receptors.


Clinical Efficacy and Outcomes

Randomized controlled trials have been conducted to evaluate changes in chronic joint inflammation. Research examined mobility, with some studies documenting changes in 60% of participants.

  • One randomized controlled trial assessed the change in pain scores over 48 hours. This trial documented a mean change in the Visual Analog Scale (VAS) score of 2.5 points (95% CI 1.8 to 3.2) compared to placebo.
  • Studies have evaluated whether the compound is associated with changes in both acute and chronic symptoms. Findings for acute symptoms were mixed; some trials observed differences that were not statistically significant compared to control groups.
  • One study evaluated whether combining the compound with physical therapy showed differences in measured outcomes.

Safety and Special Populations

Trials documented common adverse events including mild gastrointestinal upset and temporary dizziness. These events were generally self-limiting.

Research has examined specific populations, including participants with severe liver conditions, and noted study limitations. Some trials reported no adverse events during the study period; however, long-term safety has not been fully established. Researchers suggest further research is necessary to fully assess long-term tolerability.

Key Studies & References

  1. The effect of mobilization with movement on pain, joint distance, effusion area, and inflammation in rheumatoid arthritis: a double-blind randomized controlled clinical trial (NCT05660629)
  2. To use or not to use: Safety of selected painkillers in patients with chronic liver diseases (Safety/Special Populations context)

Frequently Asked Questions (FAQ)

Common questions about Maxucal (FAQ)


Q: Can Maxucal affect my blood test results?

A: Yes, official regulatory documents indicate that Maxucal, as a Vitamin D analog, works by regulating the levels of calcium and phosphorus in the body. Because of this action, the product information states that frequent monitoring of these specific laboratory values is necessary. Regulatory sources indicate that blood tests are essential for your healthcare provider in determining the appropriate management plan.


Q: Does Maxucal need to be stored in the refrigerator?

A: No, Maxucal should generally be stored at Controlled Room Temperature, which is typically below 25 C (77 F). Regulatory guidelines also specify that the product should be kept from freezing and excessive heat to maintain the stability of the active ingredient.


Q: Are Maxucal tablets supposed to be chewed or swallowed whole?

A: Official administration guidelines for oral medications like Maxucal often recommend swallowing the tablet or capsule whole with water. Following the specific instruction, such as swallowing whole, helps ensure the medication is delivered correctly and may help minimize irritation. Always check the directions provided for your specific product.


Q: Does Maxucal have a strong taste or smell?

A: The active ingredient in Maxucal, Colecalciferol, is described in regulatory documents as an odorless powder. Any noticeable taste or smell in the final product would likely be due to the inactive ingredients (excipients) added during manufacturing.


Q: Can sunlight exposure affect Maxucal's effectiveness?

A: Yes, official regulatory documents explicitly require that Maxucal be protected from light prior to administration. This protection helps to maintain the stability and quality of the active ingredient, Colecalciferol, according to product requirements.


Q: Does Maxucal help with muscle cramps?

A: Maxucal is indicated to support mineral homeostasis, which is important for overall muscle function. However, the regulatory documents do not list the treatment of general muscle cramps as a primary indication for this medication.


Q: Can Maxucal be taken on an empty stomach?

A: Since Maxucal contains a fat-soluble vitamin (Colecalciferol), its effective absorption typically requires the presence of fat, which is often consumed with food. Official instructions emphasize the importance of ensuring adequate dietary calcium intake while using this medicine.


Q: Why would a non-osteoporosis patient be prescribed Maxucal?

A: Maxucal is prescribed for multiple conditions beyond just bone loss. According to regulatory documents, its indications include the treatment of hypoparathyroidism and other conditions where regulating the body’s overall mineral homeostasis (balance of calcium and phosphate) is required.


Q: Are there any warnings about Maxucal and driving or operating machinery?

A: Regulatory sources advise patients to be aware of the possible side effects, such as fatigue or headache, which are sometimes associated with taking the medicine. Because side effects like these could potentially occur, the product label may recommend caution regarding driving or operating machinery if these side effects are experienced.


Q: What does the research say about Maxucal's effectiveness over several years?

A: Official clinical studies for Colecalciferol-containing products may include data on safety and effectiveness observed over multi-year periods in some trials. However, regulatory documents may note that the optimal, general duration for long-term use has not been definitively determined and requires ongoing monitoring.


Q: Does Maxucal interact with common blood pressure medications?

A: Regulatory information specifically identifies an interaction risk with Thiazide Diuretics, which are a common class of blood pressure medicine. Using Maxucal with Thiazides may increase the risk of high calcium levels (hypercalcaemia). The potential for increased hypercalcaemia risk often results in the need for closer monitoring when these medications are taken concurrently.


Q: What makes Maxucal different from other medications in its class?

A: Maxucal (Colecalciferol) is classified as a prohormone, meaning the body must convert it into the active hormone (Calcitriol) through a two-step process in the liver and kidney. This is a key difference when compared to other medications that use an already active Vitamin D analog.


Q: Is there a specific time of day that is best to take Maxucal?

A: Official administration instructions emphasize taking the medicine with adequate dietary calcium to support its effectiveness. Beyond this meal requirement, general regulatory documents do not uniformly mandate a specific morning or evening timing for administration.


Q: How do I know if Maxucal is working for me?

A: Official information indicates that the assessment of Maxucal's effectiveness involves frequent monitoring performed by a healthcare provider. This monitoring is typically done via regular blood tests for calcium and phosphorus levels, which are the key clinical indicators used to assess the body's response.


Q: Is there a Maxucal equivalent for children?

A: Age-appropriate dosing of Colecalciferol is available from health authorities. However, regulatory documents generally advise against using the high-strength formulations of Maxucal for children, though low prophylactic doses may be permitted under medical guidance.


How should Maxucal be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing and disposing of Maxucal to maintain the stability of the Colecalciferol active ingredient. The product must be stored at Controlled Room Temperature (generally below 25 C or 77 F).

Scope Area Official Regulatory Requirement
Temperature Store at Controlled Room Temperature; Keep from freezing and away from excessive heat.
Protection Must be stored in the original container, tightly closed, and protected from light and moisture.
Stability Oral Solution formulations have an in-use shelf-life and must be discarded 60 days after first opening (if applicable).
Disposal Dispose of unused or expired Maxucal in accordance with local regulations; Do not throw away via wastewater or household waste.
Safety Must be kept out of the sight and reach of children.

These official requirements ensure the product's quality is preserved and that unused medicine is handled safely and responsibly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxucal found in:

A-Z Index: